Brii Biosciences Launches Dual — Targeting siRNA Drug Discovery Platform
Brii Biosciences launched BRiSC today, a proprietary discovery platform for next-generation, dual-targeting small interfering RNA therapies. The platform is designed to enable a single treatment to silence two distinct targets, initially focusing on prevalent metabolic dysfunctions. Four complementary technologies aim